Ming Zhang, Jianying Wang, Tianwei Gao, Xin Chen, Yan Xu, Xiaoting Yu, Xianyang Guo, Rong Zhuang, Ziwei Li, Hongjin Wu* and Juehua Yu* Pages 349 - 356 ( 8 )
<P>Background: SOX15 is a crucial transcription factor involved in the regulation of embryonic development and in the cell fate determination. It is also an important mediator of tumorigenesis in cancer. </P><P> Methods: Here, we sought to explore the expression patterns and biological functions of SOX15 in esophageal squamous cell carcinomas (ESCC). SOX15 was found aberrantly overexpressed in ESCC tumors. </P><P> Results: Experimentally, inhibition of SOX15 through RNAi suppressed cell proliferation in ESCC cells and sensitized cancer cells to paclitaxel, but not to Cisplatin. Moreover, inhibition of SOX15 significantly repressed the expression of genes associated with WNT and NOTCH signaling pathways, which may contribute to the increased sensitivity to paclitaxel. </P><P> Conclusion: In conclusion, the current study revealed that inhibition of SOX15 in ESCC cells sensitizes the ESCC cells to paclitaxel, suggesting that the SOX15 expression level may predict the therapeutic outcomes for paclitaxel treatment for ESCC.</P>
SOX15, ESCC, Paclitaxel, RNAi, WNT, NOTCH.
Department of ICU, Hangzhou Cancer Hospital, Hangzhou, 320001, Zhejiang, Department of ICU, Hangzhou Cancer Hospital, Hangzhou, 320001, Zhejiang, Department of ICU, Hangzhou Cancer Hospital, Hangzhou, 320001, Zhejiang, Department of ICU, Hangzhou Cancer Hospital, Hangzhou, 320001, Zhejiang, Department of ICU, Hangzhou Cancer Hospital, Hangzhou, 320001, Zhejiang, Department of ICU, Hangzhou Cancer Hospital, Hangzhou, 320001, Zhejiang, Department of Anesthesiology, Critical Care and Pain Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, Zhejiang, Department of Anesthesiology, Critical Care and Pain Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, Zhejiang, Key Laboratory of Drug Addiction Medicine, Ministry of Health, The First Affiliated Hospital, Kunming Medical University, Kunming, 650032, Yunnan, Department of ICU, Hangzhou Cancer Hospital, Hangzhou, 320001, Zhejiang, Key Laboratory of Drug Addiction Medicine, Ministry of Health, The First Affiliated Hospital, Kunming Medical University, Kunming, 650032, Yunnan